Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income (2016 - 2025)

KalVista Pharmaceuticals' Net Income history spans 11 years, with the latest figure at -$52.2 million for Q2 2025.

  • For Q2 2025, Net Income fell 11.18% year-over-year to -$52.2 million; the TTM value through Apr 2025 reached -$137.1 million, down 2.99%, while the annual FY2025 figure was -$95.0 million, 24.95% up from the prior year.
  • Net Income for Q2 2025 was -$52.2 million at KalVista Pharmaceuticals, down from -$44.5 million in the prior quarter.
  • Across five years, Net Income topped out at -$12.5 million in Q1 2021 and bottomed at -$52.2 million in Q2 2025.
  • The 4-year median for Net Income is -$34.7 million (2024), against an average of -$35.3 million.
  • The largest annual shift saw Net Income decreased 1.36% in 2021 before it plummeted 53.44% in 2024.
  • A 4-year view of Net Income shows it stood at -$12.5 million in 2021, then tumbled by 131.39% to -$29.0 million in 2023, then tumbled by 53.44% to -$44.5 million in 2024, then dropped by 17.4% to -$52.2 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Net Income are -$52.2 million (Q2 2025), -$44.5 million (Q4 2024), and -$40.4 million (Q3 2024).